Patients with overactive bladder (OAB) will be randomly assigned (like a flip of a coin) to
receive 100 units of onabotulinumtoxinA injected into the bladder at either 3 sites or 10
sites. Patient satisfaction and the effectiveness of the medication will be evaluated.
Phase:
Phase 4
Details
Lead Sponsor:
William Beaumont Hospitals
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A onabotulinumtoxinA